Atomo Diagnostics (AT1.AX) Stock Price

Atomo Diagnostics Ltd. generates revenue through the sale of integrated rapid diagnostic test (RDT) devices for blood-based testing, targeting professional and self-testing markets. The company commercializes products like Atomo HIV Self-Test, AtomoRapid HIV (1&2), and ATOMONOW Pregnancy Test, which are supplied under global supply agreements for infectious disease applications including COVID-19, HIV, viral vs bacterial differentiation, and female health. These devices simplify testing procedures with patented technology, offering 15-minute results for HIV screening and blood-based diagnostics. Professional healthcare providers and consumers purchasing self-testing kits form the primary customer segments, with the firm focusing on point-of-care and at-home testing applications. The company’s revenue streams are derived from direct sales of its patented RDT devices, which are designed for both professional use and self-testing. Atomo HIV Self-Test is marketed for HIV screening with results in 15 minutes, while AtomoRapid HIV (1&2) integrates multiple test components into a single device requiring a small blood drop for 15-minute results. These products are sold globally under supply agreements targeting infectious disease diagnostics, including pandemic responses for COVID-19 and ongoing HIV testing needs. The business model emphasizes reliability and usability, appealing to healthcare institutions and individual consumers seeking rapid, accurate diagnostic solutions. Atomo Diagnostics Ltd. focuses on commercializing blood-based RDTs for specific applications, with its products targeting infectious disease testing such as HIV, viral vs bacterial differentiation, and female health. The firm’s supply agreements cover global markets, enabling sales of integrated devices like AtomoRapid HIV (1&2), which consolidates multiple test functions into one platform. Revenue is generated through the sale of these branded devices, with the Atomo HIV Self-Test and ATOMONOW Pregnancy Test serving as key offerings for self-testing segments. Professional healthcare providers and consumers purchasing self-testing kits represent the core customer base driving the company’s revenue model.